Clinical trial
A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B…
NCT00498212 · Dynavax Technologies Corporation, Industry · Terminated
Key facts
| NCT number | NCT00498212 |
|---|---|
| Title | A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease |
| Official title | A Phase 2, Single-Blind, Randomized Study of Safety and Immunogenicity Following Vaccination With Single or Double Doses of HEPLISAV™ in Adults With End-Stage Renal Disease |
| Lead sponsor | Dynavax Technologies Corporation, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Biological |
| Interventions | 1018 ISS-HBsAg-Single, 1018 ISS-HBsAg-Double |
| Enrollment | 41 |
| Start date | Jul 1, 2007 |
| Primary completion | Aug 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Jul 9, 2007 |
| Last update posted | Mar 26, 2019 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: